April 25th in Osteoporosis Drugs by Vivian Goldschmidt, MA .
When I read a brand new study just published last week in the Journal of Clinical Endocrinology & Metabolism, it was like a breath of fresh air. “At last! Mainstream scientists are telling the truth about this toxic and dangerous osteoporosis drug”, I thought to myself.
But then I began to wonder – why did it take so long for this information to surface? After all, I …
April 15th in Osteoporosis Drugs by Vivian Goldschmidt, MA .
Today, there’s a lot to cover on the latest osteoporosis news. From lawsuits against Merck to mad science and more.
March 31st in Osteoporosis Drugs by Vivian Goldschmidt, MA .
New scientific discoveries can lead to great things, but it’s important to recognize just what the larger purpose is in any scientific venture. Here’s how you can tell the difference: when the purpose of scientific research is solely to create and market new drugs, then that’s a red flag.
Today I am going to share a recent study with you that seems to answer a 200-year-old question: how …
March 21st in Osteoporosis Drugs by Vivian Goldschmidt, MA .
Five years ago, a study showed that a common, cheap, over-the-counter drug helps maintain bone density.
So why didn’t this news make major headlines?
After all, this should be excellent news to the Medical Establishment, since they believe that osteoporosis is a disease that must be treated with drugs. How is it that a readily available over-the-counter drug that apparently does the trick is not heralded as …
March 12th in Osteoporosis Drugs by Vivian Goldschmidt, MA .
As you may have probably noticed by now, the FDA tends to backpedal.
They overlook risks and side effects and approve drugs to market. Then, after the drug has done plenty of damage, here comes the FDA again, warning of the drug’s risks.
It’s happened once again with a long-established, rather “fishy” osteoporosis drug.
Thankfully, the Save Our Bones Program is on the cutting edge. From the get-go …
March 10th in Osteoporosis Drugs by Vivian Goldschmidt, MA .
Once again, we’re entering the realm of taboo subjects. The information I’m about to reveal today is so hush-hush that your doctor probably doesn’t even know about it.
A new study from Canada reveals something very disturbing for those over the age of 50 who take a certain class of drugs.
Antidepressants: Something to be Sad About
We are a sad nation, apparently…a sad continent, actually, given that …
March 4th in Osteoporosis Drugs by Vivian Goldschmidt, MA .
It seems there’s always news in the osteoporosis community. And it’s going to stay that way for quite some time, courtesy of Big Pharma. Today, the spotlight is (yet again) on Merck and its popular osteoporosis drug, Fosamax.
“Dear Merck: Please make a safer drug than Fosamax! – signed, the FDA”
While that’s a fictional quote, it sums up what’s going on between pharmaceutical giant Merck and the …
February 10th in Osteoporosis Drugs by Vivian Goldschmidt, MA .
One of my primary commitments is to keep you up-to-date on the latest osteoporosis news, including the most recent osteoporosis research and drugs. Today you’ll read about a newly discovered side effect of a blockbuster drug and the mysterious delay for approval application of what could become the next best-selling osteoporosis drug.
So let’s get started…
December 13th in Osteoporosis Drugs by Vivian Goldschmidt, MA .
A brand-new study by scientists at Columbia University Medical Center paves the way for doctors to prescribe even more bisphosphonate drugs. Researchers found that certain variations in specific genes actually increase the risk of developing one of the most devastating side effects of bisphosphonates.
These findings allow doctors to screen patients so as to discern who would be the most likely to suffer from Ostenonecrosis of the Jaw …
October 10th in Osteoporosis Drugs by Vivian Goldschmidt, MA .
Did you notice that there are no Boniva ads on TV lately? In case you wonder why Sally Field’s career as its spokesperson has been suddenly “grounded”, I have the answer. You see, Boniva’s patent expired in March of this year, so the FDA immediately approved the generic version of the hugely popular osteoporosis drug.1
Now that doctors can prescribe the bisphosphonate ibandronate sodium instead of Boniva, the …